Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension?
Open Access
- 5 December 2024
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 987, 177175
Abstract
No abstract availableKeywords
This publication has 181 references indexed in Scilit:
- Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrumEuropean Journal of Heart Failure, 2022
- Vericiguat in Combination with Short‐Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE StudyClinical Pharmacology & Therapeutics, 2022
- Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fractionEuropean Journal of Heart Failure, 2022
- Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection FractionJAMA, 2020
- Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection FractionJAMA, 2020
- Management of Low Blood Pressure in Ambulatory Heart Failure with Reduced Ejection Fraction PatientsEuropean Journal of Heart Failure, 2020
- A Randomized, Placebo‐Controlled, Multiple‐Ascending‐Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy SubjectsClinical Pharmacology in Drug Development, 2018
- Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection FractionJAMA, 2015
- Rationale and Design of The SOluble guanylate Cyclase StimulatoR in HeArT FailurE Studies (SOCRATES)European Journal of Heart Failure, 2014
- Discovery of Riociguat (BAY 63‐2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary HypertensionChemMedChem, 2009